Screening for EGFR mutations in lung cancer, a report from India
Authors:
- Rashmita SahooRSRashmita Sahoo
- Vidya Harini VVVVidya Harini V
- V. Chitti BabuVBV. Chitti Babu
- Geeta V. Patil OkalyGOGeeta V. Patil Okaly
- Smitha RaoSRSmitha Rao
- Ashwini NargundANAshwini Nargund
- E. VenkataswamyEVE. Venkataswamy
- Raghavendra RaoRRRaghavendra Rao
- B.S. Ajai KumarBKB.S. Ajai Kumar
- 1 September 2011
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 73 (3) , 316-319
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Population-based differences in treatment outcome following anticancer drug therapiesThe Lancet Oncology, 2010
- EGFR Signaling and Drug DiscoveryOncology, 2009
- Cetuximab, its clinical use and future perspectivesAnti-Cancer Drugs, 2008
- Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectivesExpert Review of Molecular Diagnostics, 2007
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Opportunities and challenges in the development of kinase inhibitor therapy for cancerGenes & Development, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001